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Strategy for the Use of Erythropoetin Alpha to Maintain Hemoglobin Level in Breast 
Cancer Patient Treated with Anthracycline-base of Adjuvant Chemotherapy 
Abstract  Objective: To evaluate the value of erythropoietin alpha (epoetin) administration, 
as an alternative treatment of anemia in the operable breast cancer patients.
 Methods: This is a multicenter phase III randomized clinical trial to evaluate the 
value of epoetin administration among anemic breast cancer patients who are 
undergoing anthracyclin-based adjuvant chemotherapy. Sixty four patients were 
incuded in this trial with initial hemoglobin (Hb) level of 10–12 g/dL. The patients 
were randomly distributed into two groups: one group received aministration of 
40,000 IU epoetin/week for six times a week after operation and the other did 
not.  In the third week after the operation, both groups were started on a 6 cycles 
of adjuvant chemotherapy with three weeks intervals. Hb levels were evaluated 
during every chemotherapy cycle. 
 Results: The Hb levels in the epoetin group were always above 10 g/dL up until 
the end of the sixth chemotherapy cycle or until the twenty first week post 
operation without blood transfusion. 
 Conclusions: The administration of epoetin 3 weeks prior and 3 weeks after the 
first cycles of chemotherapy, maintains a sufficient/normal Hb level in breast 
cancer patients receiving anthracycline-based chemotherapy.
 Keywords: Anthracyclin-based chemotherapy, breast cancer, erythropoietin 
alpha
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Introduction 
In the management of operable breast cancer 
with histopathologically proven lymph nodes 
metastasis, adjuvant chemotherapy has to be 
given.1 For optimal adjuvant chemotherapy 
result, drug type accuracy, dosage and consistent 
schedule have to be obtained. However, the 
inconsistency in therapy sometimes occured 
due to the side effects of chemotherapy on the 
hematopoietic system, causing a decrease in 
the hemoglobin level.
In several studies, some researchers reported 
that anthracycline-based chemotherapy could 
lead to 4–63% of anemia, depending on the 
number of chemotherapy cycles.2 It is also 
reported that 25% patients who received 21-day 
cyclophosphamide, epirubicin, 5-fluorouracil 
(CEF) regiment [600/60/600 mg/m2] developed 
anemia.3 Other researchers have reported 
that anemia occurred at the beginning of the 
first week of chemotherapy in 88.3% patients 
receiving adriamycin-cyclophosphamide (AC) 
regiments [60/600 mg/m2, three weekly].3 Blood 
transfusion is the recommended treatment for 
chemotherapy related anemia. The result is fast 
achieved but the side effect of blood transfusion 
should not be ignored. These side effects 
ranging from allergic reaction to anaphylactic 
shock with possible risks for viral infections such 
as hepatitis and human immunodeficiency virus 
(HIV) infections.4
In 2002, the American Society of Clinical 
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of erythropoietin alpha (epoetin) as a therapy 
for chemotherapy induced anemia.5 Epoetin 
boosts erythrocyte production by proliferating 
and differentiating the erythroid precursor in 
the bone marrow. It also stimulates reticulocyte 
release from bone marrow and increases 
cellular hemoglobin (Hb) synthesis due to colony 
forming unit-erythroid (CFU-E) differentiation 
into erythroblast.6-10 ASCO recommended that 
epoetin treatment should be started when the 
Hb level is ≥10 g/dL but also in mild anemia where 
the Hb level is 10–12 g/dL. The recommended 
dosage is 150 IU/kg, three times a week or 
40,000 IU once a week.5 Del Mastro and Venturini 
reported that in 20–40% cases of patients with 
Hb <10 g/dL, transfusion was still required even 
after epoetin alpha was given.6 This failure may 
account to the delay in treatment, since epoetin 
response in cancer patients occurred in a range 
of 3–12 weeks.
An alternative strategy that can be selected is 
to use epoetin to prevent the occurence of severe 
anemia in patients with normal Hb level or mild 
anemia.  The goal of this third phase clinical trial, 
which was to understand the role of epoetin 
alpha in maintaining Hb levels in breast cancer 
patients who was receiving anthracycline-based 
adjuvant chemotherapy. Positive results of this 
clinical trial would suggest the use of epoetin 
alpha to replace blood transfusion and may 
also be used as a consideration in developing 
treatment protocols for operable breast cancer 




This trial involved two groups of operable breast 
cancer patients, the erythropoietin and control 
groups. The inclusion criteria were having 
undergone a modified radical mastectomy with 





FEC) adjuvant chemotherapy. Patients with 
anemia due to other causes such as nutritional 
deficiency, renal malfunction, vitamin (iron, folic 
acid and B12) deficiency and hypersplenism 
were excluded from the trial.
This is a multicenter third phase clinical trial 
study in Department of Surgical Oncology, Dr. 
Hasan Sadikin General Hospital, Bandung, West 
Java; Dr. Kariadi General Hospital, Semarang, 
Central Java; and Dr. Soedarso General Hospital, 
Pontianak, Kalimantan with paralleled design, 
1:1 randomize-controlled. Approval was gained 
from the Ethical Committee of Dr. Hasan Sadikin 
General Hospital, Bandung, Indonesia. 
Subjects who met the inclusion criteria were 
recorded and randomly distributed into the 
group receiving epoetin or control group. One 
week folowing the radical matectomy surgery, 
the epoetin group was given 40,000 IU/week 
epoetin alpha for 6 times. In the 3rd week both 
groups underwent adjuvant chemotherapy for 
6 cycles with 3 weeks intervals. Hb levels were 
evaluated in every chemotherapy cycle.
Table 1 Patient Characteristics
Characteristics Epoetin alpha (n=32) Control (n=32)
Age (yrs.)
     Mean±SD 43.63±8.167 45.13±8.393
     Range 30–63 24–61
Stage
     IIA 30 (93.7%) 2 (6.25%)
     IIB - 29 (90.6%)
     IIIA 2 (6.3%) 1 (3.12%)
Hemoglobin (g/dL)
     Mean±SD 11.1±0.67 11.16±0.74
     Median 10.9 10.9
SD, Standard Deviation
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The level of hemoglobin in the 3rd, 6th and  21st 
week in both groups were analyzed statistically 
by using unpaired t-test technique. Data analysis 
was performed using SPSS for Windows version 
13.0. with 95% degree of confidence with a 
p-value of ≤ 0.05.
Results 
Effectiveness and safety evaluation
Sixty four patients were recruited from three 
centers (Bandung, Semarang, and Pontianak) 
where 32 patients were given epoetin alpha and 
32 patients were included in the control group.
The demographic and characteristic distributions 
of the patients were generally equal in both 
groups (Table 1).
Need of transfusion
No transfusion was needed during chemotherapy 
in the epoetin alpha group. In contrast, 9 (28.1%) 
patients in the control group needed transfusion. 
Transfusion was mostly required after the 4th 
cycle or the 12th week post-operation (5 patients, 
15.6%) (Table 2).
Hematopoetic responses
It shows the mean level of hemoglobin from the 
beginning of the clinical trial up to the 21st week 
in both groups (Fig. 1). Patients in the epoetin 
alpha group showed a gradual elevation in the 
mean hemoglobin level, visible in the 3rd week, 
and reached the hemoglobin level of 12 g/dL 
after the 6th week and maintained the level of 
around 11.5 g/dL until the 21st week. There were 
significant differences from the 3rd week onward 
(Table 3).
Discussion 
Anemia is a common condition found among 
cancer patients, caused by either the cancer 
itself, blood loss in the operating procedure, 
chemotherapy or radiation anemia which will 
affect the whole organ and tissue function, 
prognosis of therapy, morbidity, and survival 
rates of the patient. The common cause of anemia 
in cancer patients is the cancer itself that causes 
inadequate production of erythropoietin and 
vitamin deficiencies (iron, folic acid, and B12), 
infiltration of cancer cells to the bone marrow, 
excessive bleeding during the operation, and 
bone marrow suppression after chemotherapy 
or radiation. Previous randomized double blind 
clinical trials with larger sample numbers had 
shown that recombinant epoetin alpha was 
effective in treating anemia and was safe for 
cancer patients.7,8 However, these earlier studies 
were generally focused in correction of anemia 
on patients with hemoglobin levels below 10.5 
Table 2 The Need of Transfusion During Chemotherapy
Chemotherapy periods Weeks Epoetin group (n=32) Control group (n=32)
1st chemotherapy 3 - -
2nd chemotherapy 6 - 2
3rd chemotherapy 9 - 1
4th chemotherapy 12 - 5
5th chemotherapy 15 - 1
6th chemotherapy 18 - -
Percentage (%) 0 (0%) 9 (28.1%)
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Table 3 Statistical Analysis  of Hemoglobin Level at Week 3, 6 and 21












10.7 0.71 ̶ 1.34 <0.001
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or 11 g/dL, thus circumventing the need for 
blood transfusion. The benefit of epoetin as a 
prophylaxis againts anemia in patients undergo 
chemotherapy has not been fully attested.
Savonije et al.9 compared the admistration of 
epoetin alpha to supportive therapy on cancer 
patients who underwent chemotherapy with a 
goal of evaluating hematologic parameters and 
the need for transfusion. The study involved 
316 patients with hemoglobin stratification 
baseline <9.7 g/dL, 9.7–10.5 g/dL, 10.5–11.3 g/
dL and >11.3 g/dL. The study has shown that 
erythropoietin increased the Hb level significantly 
and decreased the need of transfusion. Patients 
with mild anemia in the epoetin group were able 
to maintain their Hb level steady and decrease 
the need for transfusion, which was also seen 
among patients with a higher initial Hb level. In 
this study 40,000 IU epoetin alpha was given per 
week to each patient, started 2 weeks prior to 
anthracycline-based chemotherapy up to the 
2nd cycle or for 6 weeks. It showed that patients 
receiving epoietin were able to maintain their Hb 
level above 10 g/dL until the end of the 6th cycle 
of chemotherapy or until the 21st weeks after the 
operation without blood transfusion. 
Six weeks adminstration of epoetin alpha 
therapy, three weeks prior and three weeks 
after the first cycle of anthracyclin-based 
chemotherapy, maintains the hemoglobulin level 
in breast cancer patients receiving anthracycline-
based chemotherapy.
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Fig. 1 Mean Level of Hemoglobin During the Clinical Trial
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